Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15137456 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3885456 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL8429329 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1668605 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9232535 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1666797 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1666654 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL5577129 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL3171119 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9235193 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 183 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298352-B1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD (JP) | 2015-01-14 | — | — | EP | claimed |
| US-20100172845-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | claimed |
| WO-2009002652-A9 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | UNIV TEXAS (US) | 2009-02-12 | — | — | WO | claimed |
| WO-2009002652-A2 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | UNIVERSITY OF FUKUI (JP) | 2008-10-30 | — | — | US | claimed |
| US-20240192707-A1 | MICROFLUIDIC SYSTEM | THE UNIVERSITY OF CHICAGO | 2024-06-13 | — | — | US | disclosed |
| US-20240160231-A1 | MICROFLUIDIC SYSTEM | THE UNIVERSITY OF CHICAGO | 2024-05-16 | — | — | US | disclosed |
| EP-3891102-B1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC (CA) | 2024-04-17 | — | — | EP | disclosed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-11853087-B2 | Microfluidic system | THE UNIVERSITY OF CHICAGO (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023190099-A1 | METHOD FOR MEASURING SUBSTANCE OF INTEREST, CAPTURE CARRIER, MEASUREMENT KIT, AND METHOD FOR MANUFACTURING MEASUREMENT REAGENT | 株式会社ビー・エム・エル | 2023-10-05 | — | — | WO | disclosed |
| US-20230035776-A1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC. (CA) | 2023-02-02 | — | — | US | disclosed |
| US-20050087122-A1 | Device and method for pressure-driven plug transport and reaction | THE UNIVERSITY OF CHICAGO | 2005-04-28 | — | — | US | disclosed |
| US-20050062196-A1 | Microfluidic protein crystallography techniques | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2005-03-24 | — | — | US | disclosed |
| EP-1508044-A2 | DEVICE AND METHOD FOR PRESSURE-DRIVEN PLUG TRANSPORT AND REACTION | The University of Chicago (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20050019794-A1 | Crystal growth devices and systems, and methods for using same | FLUIDIGM CORPORATION (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040115731-A1 | Microfluidic protein crystallography | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2004-06-17 | — | — | US | disclosed |
| WO-2004038363-A2 | MICROFLUIDIC DEVICE AND METHOD FOR PRESSURE-DRIVEN PLUG TRANSPORT AND REACTION | THE UNIVERSITY OF CHICAGO (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | IDEA AG (DE) | 2004-04-15 | — | — | US | disclosed |
| US-20030061687-A1 | High throughput screening of crystallization materials | CALIFORNIA INSTITUTE OF TECHNOLOGY, A CALIFORNIA CORPORATION | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040071767-A1 | NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery | SLC43A1, TRPV2, TRPA1 | LGALS3 2616/4885LGALS1 3309/4885LGALS9 2711/4885 |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | GZMB, RNASE1, CASP3 | LGALS3 80/4885LGALS1 98/4885LGALS9 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.